AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2023
Dec 26, 2023
65314_rns_2023-12-26_2c7038f8-0d48-4e7c-abdf-d1338baaee33.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX Release 27 December 2023
ASX Code: MEM
==> picture [187 x 51] intentionally omitted <==
EXTENSION OF PRO-RATA NON-RENOUNCEABLE ENTITLEMENT ISSUE
Memphasys Limited (ASX: MEM) (the “Company”) refers to the pro-rata non-renounceable entitlement offer ( Offer ) dated 4 December 2023 and that was despatched to shareholders on 13 December 2023.
The Offer is for two (2) fully paid ordinary shares (Share) for every nine (9) Shares held by those eligible shareholders registered at the record date of Friday 8 December 2023 (Record Date) at an issue price of $0.01 per Share (Offer) together with one (1) free New Option for every two (2) Shares applied for and issued, to raise up to approximately $2,132,268.
The Company advises that it has extended the closing date of the Offer, that will now close on Monday, 9 January 2024.
The new timetable is as follows:
| Closing Date as at 5:00pm AEDT* | 9 January 2024 |
|---|---|
| Shares quoted on a deferred settlement basis | 10 January 2024 |
| ASX and Underwriter notified of under subscriptions | 12 January 2024 |
| Underwriter subscribes for Shortfall under terms ofUnderwritingAgreement | 16 January 2024 |
| Issue date and lodgement of Appendix 2A with ASX applying forquotation of the Shares (before noon, Sydney time) | 16 January 2024 |
| Quotation of Shares issued under the Entitlement Offer* | 17 January 2024 |
| General Meeting of the Company | early February 2024 |
| Issue date of New Options under the Placement Options offer | early February 2024 |
- The Directors may extend the Closing Date by giving at least 3 Business Days ‘notice to ASX prior to the Closing Date. Accordingly, the date the Shares are expected to commence trading on ASX may vary.
This release is authorised by the Board of Directors of Memphasys Limited.
For further information please contact: Mr Andrew Metcalfe Company Secretary E: [email protected] P: +61 2 8415 7300
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations and reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix[TM] device, combines electrophoresis with proprietary size exclusion membranes to separate sperm cells for human artificial reproduction. Website: www.memphasys.com